Alnylam Takes Platform Monetization to a Whole New and Non-Exclusive Level
Alnylam's monster deal with Roche for non-exclusive rights to the biotech's RNAi platform across four therapeutic areas sets the bar for technology platform monetization. Not only is Alnylam gaining $331 million in upfront payments, it can turn around and re-license those same rights at any time. Roche is for the first time making a splash in RNAi, which it and other companies are betting will be a new therapeutic modality.
You may also be interested in...
Can CRISPR Make The Jump To Therapeutics?
Biomedical researchers are rapidly adopting the new gene-editing technology CRISPR/Cas9 for lab experiments, but can CRISPR also become the basis for new treatments of human disease? At least two venture-backed start-ups can't wait to find out.
Finding Gold In An Unfavored Space: Servier And MicroRNA Start Up Miragen In CV Deal
Starting with a $45 million upfront, the potential value of this deal, which centers on three pre-clinical cardiovascular targets, could reach up to $1 billion, if the companies meet regulatory and commercial milestones.
Alnylam Shifts To Product-Focused Strategy As RNAi Platform Takes A Hit
Alnylam Pharmaceuticals' strategy announcement on Jan. 7 was “a transformation,” CEO John Maraganore said in an interview at the J.P. Morgan Healthcare Conference, emphasizing that he has “never been more excited” about the prospects for his company.